Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5‐Fluorouracil, and Leucovorin Versus Oxaliplatin, 5‐Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG‐ACRIN Research Group (E5204)

Background The addition of bevacizumab to chemotherapy improved outcomes for patients with metastatic colon cancer. E5204 was designed to test whether the addition of bevacizumab to mFOLFOX6, following neoadjuvant chemoradiation and definitive surgery, could improve overall survival (OS) in patients...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2020-05, Vol.25 (5), p.e798-e807
Hauptverfasser:	Chakravarthy, A. Bapsi, Zhao, Fengmin, Meropol, Neal J., Flynn, Patrick J., Wagner, Lynne I., Sloan, Jeffrey, Diasio, Robert B., Mitchell, Edith P., Catalano, Paul, Giantonio, Bruce J., Catalano, Robert B., Haller, Daniel G., Awan, Rashid A., Mulcahy, Mary F., O'Brien, Timothy E., Santala, Roger, Cripps, Christine, Weis, John R., Atkins, James N., Leichman, Cynthia G., Petrelli, Nicholas J., Sinicrope, Frank A., Brierley, James D., Tepper, Joel E., O'Dwyer, Peter J., Sigurdson, Elin R., Hamilton, Stanley R., Cella, David, Benson, Al B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant therapy Antiangiogenesis Avastin Bevacizumab Gastrointestinal Cancer Rectal cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!